Literature DB >> 27176078

CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.

Malinee Thanee1,2, Watcharin Loilome1,2, Anchalee Techasen2,3, Eiji Sugihara4, Shogo Okazaki4, Shinya Abe5,6, Shiho Ueda5, Takashi Masuko5, Nisana Namwat1,2, Narong Khuntikeo2,7, Attapol Titapun2,7, Chawalit Pairojkul2,8, Hideyuki Saya4, Puangrat Yongvanit1,2.   

Abstract

Expression of CD44, especially the variant isoforms (CD44v) of this major cancer stem cell marker, contributes to reactive oxygen species (ROS) defense through stabilizing xCT (a cystine-glutamate transporter) and promoting glutathione synthesis. This enhances cancer development and increases chemotherapy resistance. We investigate the role of CD44v in the regulation of the ROS defense system in cholangiocarcinoma (CCA). Immunohistochemical staining of CD44v and p38(MAPK) (a major ROS target) expression in Opisthorchis viverrini-induced hamster CCA tissues (at 60, 90, 120, and 180 days) reveals a decreased phospho-p38(MAPK) signal, whereas the CD44v signal was increased during bile duct transformation. Patients with CCA showed CD44v overexpression and negative-phospho-p38(MAPK) patients a significantly shorter survival rate than the low CD44v signal and positive-phospho-p38(MAPK) patients (P = 0.030). Knockdown of CD44 showed that xCT and glutathione levels were decreased, leading to a high level of ROS. We examined xCT-targeted CD44v cancer stem cell therapy using sulfasalazine. Glutathione decreased and ROS increased after the treatment, leading to inhibition of cell proliferation and induction of cell death. Thus, the accumulation of CD44v leads to the suppression of p38(MAPK) in transforming bile duct cells. The redox status regulation of CCA cells depends on the expression of CD44v to contribute the xCT function and is a link to the poor prognosis of patients. Thus, an xCT inhibitor could inhibit cell growth and activate cell death. This suggests that an xCT-targeting drug may improve CCA therapy by sensitization to the available drug (e.g. gemcitabine) by blocking the mechanism of the cell's ROS defensive system.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Entities:  

Keywords:  CD44v; cholangiocarcinoma; opisthorchiasis; redox status; sulfasalazine

Mesh:

Substances:

Year:  2016        PMID: 27176078      PMCID: PMC4946726          DOI: 10.1111/cas.12967

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


CD44 is a single transmembrane protein that is involved in several physiological and pathological processes, including cancer development.1, 2 It is expressed in a wide variety of isoforms and can be used as a cell surface marker in order to identify CSCs in many cancer types.3, 4, 5, 6 Moreover, expression of CD44v on the cell surface stabilizes xCT and contributes GSH synthesis for ROS defense. xCT is a cystineglutamate transporter that promotes cystine uptake and then its conversion to cysteine (a rate‐limiting step in GSH synthesis).7 The oxidative stress affects the cellular behavior through intracellular signaling responses such as the MAPK pathways, especially p38MAPK. It is involved in cell differentiation, apoptosis, and autophagy through the activation of several kinase proteins; for instance, p21 is an important cell cycle inhibitor,8 resulting in G1 cell cycle arrest,9 senescence,10 and apoptosis.11 Furthermore, an increase in Atg proteins through p38MAPK signaling leads to the conversion of LC3‐I to LC3‐II, resulting in autophagy accumulation and cell death.12 Cholangiocarcinoma is a malignancy of the bile duct epithelial cells, mainly caused by chronic inflammation due to Ov infection in Southeast Asia, especially in northeast Thailand.13, 14, 15, 16 Chronic inflammation generates high levels of oxidants, such as ROS and nitrogen species, which can damage cellular biomolecules causing the formation of oxidation products. This can lead to mutations, genetic instability, epigenetic changes, and an alteration of gene expression.17, 18 Generally, the damaged cells undergo programmed cell death by apoptosis, autophagy, or necrosis, however, some can survive under high oxidant levels.18, 19 How the cell can survive under oxidative stress conditions is still a challenging question that needs to be clarified. The heterogeneity found in solid cancers is supported by a subpopulation of CSCs that is capable of tumor initiation and self‐renewal.20 Redox status regulation in CSCs, which can act as a link between oxidative stress and cancer development, might be one of the mechanisms to explain this phenomenon. The regulation of redox status in relation to the CD44v–xCT system in CSCs functions not only in driving the damaged cells to enter carcinogenesis processes, but also enables cancer cells to resist anticancer treatment.21, 22 Interestingly, an xCT inhibitor (SSZ) has been tested in many studies on the suppression of tumor growth, invasion, and metastasis.23, 24, 25, 26, 27 To date, there is no effective, curative chemotherapy for CCA. One explanation for this may be the alteration of the regulation of redox status by the CD44v–xCT system, leading to CCA cell resistance to chemotherapy and linking to the poor prognosis of CCA patients. Hence, the treatment of cancer cells using SSZ, which can inhibit the CD44v–xCT system, may impair the ROS defense mechanism of cancer cells and sensitize them to available anticancer drugs. In the present study, we report, for the first time, an altered redox status regulating Ov‐induced CCA in both a hamster model and humans. We also reveal the function of CD44 in the regulation of the ROS defense system in Ov‐induced CCA. Additionally, we examine xCT‐targeted CD44v‐CSC chemotherapy using SSZ, an xCT inhibitor influencing CCA cell proliferation and survival, possibly through ROS–p38MAPK–p21 signaling.

Materials and Methods

In vivo animal studies

Opisthorchis viverrini infection with N‐nitrosodimethylamine in the hamster model has been widely used to study the tumorigenesis processes of bile duct cancer.28, 29, 30 The protocol was constructed as previously described.29 In the treatment groups, animals were fed with 50 Ov metacercariae by intragastric intubation combined with the oral administration of 12.5 p.p.m. N‐nitrosodimethylamine (Sigma‐Aldrich, St. Louis, MO, USA) for 30 days; the control group was left untreated. The hamsters were killed at 60, 90, 120, or 180 days. Liver tissues were collected in paraffin blocks or frozen. All experiments were approved by Animal Ethics Committee of Khon Kaen University (Khon Kaen, Thailand) (AEKKU 23/2555).

Human tissue microarray of CCA samples

Two human tissue arrays were used in this study. The first was an Ov‐associated CCA liver tissue array (97 cases) obtained from the specimen bank of the Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University. The research protocols were approved by the Human Research Ethics Committee, Khon Kaen University (#HE571283) and informed consent was obtained from each subject before surgery. The second was a non‐Ov‐associated CCA liver tissue array (42 cases) purchased from Abcam (Cambridge, MA, USA).

Cell culture

The CCA cell lines, including KKU‐214, KKU‐213, and KKU‐100 were established from CCA patients of Srinagarind Hospital, Khon Kaen University by Professor Banchob Sripa. Certificates of analysis were obtained from Japanese Collection of Research Bioresources Cell Bank, Osaka, Japan. All cell lines were cultured in DMEM (Thermo Fisher Scientific, MA, USA), supplemented with NaHCO3, 100 U/mL penicillin, 100 mg/mL streptomycin, and 10% FBS. Cells were maintained in a humidified incubator at 37°C containing 5% CO2.

Antibodies for IHC, immunofluorescence, immunoblot, and flow cytometry analyses

For IHC and immunofluorescent staining, anti‐CD44s was purchased from BD Bioscience (BD Bioscience, Tokyo, Japan), anti‐CD44v8‐10 was purchased from Cosmo Bio (Tokyo, Japan), and anti‐total and phospho‐p38MAPK (Tyr180/182) was purchased from Cell Signaling Technology (Danvers, MA, USA.) For immunoblotting, anti‐LC3B was purchased from Abcam (Cambridge, UK), anti‐p21 was purchased from Santa Cruz (Santa Cruz Biotechnology, CA, USA) and anti‐β‐actin antibody was purchased from Sigma‐Aldrich. For flow cytometry analysis, anti‐xCT, which was generated as described previously,22 was kindly donated by the Cell Biology Laboratory and the Biological Protection Laboratory, Kindai University (Higashiosaka, Japan) and Kyoto University (Kyoto, Japan). Anti‐CD44v8‐10‐conjugated FITC and anti‐CD44s‐conjugated allophycocyanin were purchased from eBioscience (Tokyo, Japan).

Chemicals

Three chemicals used in this study, SSZ (an inhibitor of xCT), BSO (a γ‐glutamylcysteine synthetase inhibitor), and Trolox (a water‐soluble analog of vitamin E that can protect against cell damage by oxidants) were purchased from Sigma‐Aldrich.

Immunohistochemistry analysis

Liver tissues were fixed in 10% buffered formaldehyde, embedded in paraffin blocks and then sectioned at a thickness of 4 μm. Sections were deparaffinized in xylene and rehydrated in an ethanol series. Immunohistochemical staining was carried out for CD44s, CD44v8–10, and phospho‐p38MAPK according to standard methods as previously described.31 The sections were observed under a light microscope at ×200 and ×400 magnification (Axioscope A1; Carl Zeiss, Jena, Germany). The scoring system of IHC was previously described.32, 33

Immunofluorescence analysis

The tissue sections were processed for IHC staining and retrieved by heating in 0.01 M sodium citrate containing 0.05% Tween‐20 (pH 6.0) for 10 min at 110°C. For cell culture, CCA cells were fixed with 4% paraformaldehyde. The samples were then exposed to 3% BSA before being incubated at 4°C overnight with primary antibodies (CD44v8–10, phospho‐p38MAPK, and p21). The samples were washed three times with TBS, then incubated with Alexa Fluor 647‐ or 488‐conjugated secondary antibodies (Invitrogen, Tokyo, Japan), and mounted in Vestashield mounting medium containing DAPI (Vector Laboratories, Burlingame, CA, USA). Next, the stained tissues were observed under a FV1000‐D confocal microscope (Olympus, Tokyo, Japan) at ×200 and ×400 magnification.

Immunoblot analysis

The CCA cell lines (1 × 105 cells per well) were seeded into 6‐well plates for 24 h and then treated with 300 μM SSZ (Sigma‐Aldrich). The method was previously described.34 Briefly, equal amounts of protein (15 μg) were treated with SDS sample buffer. The samples were separated on 10% polyacrylamide gels by electrophoresis and transferred onto PVDF membranes. The membranes were incubated with primary antibody against total‐p38MAPK, phospho‐p38MAPK, LC3B, and β‐actin overnight at 4°C. The proteins were analyzed using chemoluminescence enhancing with an ECL Prime Western Blotting Detection System (GE Healthcare, Little Chalfont, UK). β‐Actin expression was used as an internal control.

Flow cytometry analysis

For flow cytometry (FACS) analysis, single‐cell suspensions were incubated with antibodies to CD44s, CD44v8–10, and xCT for 15 min at 4°C. Apoptotic cells were excluded during flow cytometry by elimination of cells staining positive with propidium iodide (Sigma‐Aldrich). Flow cytometry analysis was undertaken with an Attune Acoustic Focusing Cytometer (Life Technologies/Applied Biosystems, Tokyo, Japan).

CD44 siRNA transfection

Highly CD44v8–10‐expressing CCA cell lines KKU‐213 and KKU‐214 were used. The CCA cells (1 × 105 cells) were seeded into 6‐well plates for 24 h before transfection. Cells were then transfected with either control or specific target siRNAs for 24–96 h using Lipofectamine RNAi MAX reagent (Invitrogen). The siRNA specific to human CD44 mRNA (target1, 5′‐AAAUGGUCGCUACAGCAUCTT‐3′; target 2, 5′‐GUAUGACACAUAUUGCUUCTT‐3′) was obtained from JbioS (Saitama, Japan). Next, the level of CD44v8–10, xCT, ROS, phospho‐p38MAPK, and GSH were analyzed after transfection.

Measurement of GSH content

The intracellular GSH levels were examined using a GSH‐Glo Glutathione Assay kit (Promega, Madison, WI, USA). The samples were harvested and diluted in PBS to 5 × 103 cells per well in 96‐well black plates. Then GSH‐Glo Reaction Buffer containing luciferin‐NT and GST was added to the plate and incubated for 30 min. Reconstituted luciferin was then added to the plate and incubated for 15 min. The plate was read in a luminometer. This assay was normalized using a GSH standard solution provided with the kit. Data were expressed as mean ± SD of reduced intracellular GSH concentration.

Measurement of ROS level

The intracellular ROS levels were determined using DCF fluorescence staining (C6827; Invitrogen). The samples were incubated with 10 μM dichloro‐dihydro‐fluorescein diacetate (DCFH‐DA) for 15 min at 37°C, and then twice washed with PBS. The median intensity of DCF fluorescence in 10 000 cells was determined using flow cytometry. The results were analyzed using FlowJo software (Tree Star, San Carlos, CA, USA) and presented as relative fluorescence intensity.

Cell proliferation and cell cytotoxicity

The number of viable cells was evaluated with a Cell Titer‐Glo luminescence cell viability kit (Promega). Briefly, CCA cells (2 × 103 cells per well) were plated into 96‐well black plates for 24 h. Cells were then treated with SSZ (0, 200, 400, 600, 800, or 1000 μM) for 24, 48, 72, or 96 h. The luminescence signal was detected on a SpectraMax L microplate reader (Molecular Devices, CA, USA). The experiments were done in triplicate.

Statistical analysis

Statistical comparisons were carried out using spss software version 17.0 (IBM, Armonk, NY, USA). The association between protein expression in CCA tissue and patient clinical data was analyzed using the χ2‐test. Patient survival was calculated according to Kaplan–Meier with a log–rank test. All analyses were two‐tailed and P‐values < 0.05 were considered statistically significant.

Results

CD44 expression during CCA genesis in hamster model

Immunohistochemical analysis revealed an increasing positive signal of CD44s along with CD44v8–10 in the cytoplasm of the transformed cholangiocytes, including the hyperplastic bile duct, at days 60 and 90, in the dysplastic bile duct at day 120, and the malignant bile duct at day 180. The strongest expression of CD44s and CD44v appeared to occur at days 120 and 180 in both dysplasia and the malignant bile duct epithelia (Fig. 1a). The highest phospho‐p38MAPK signal (a main target of ROS signaling) was seen in the nucleus of the hyperplastic bile duct cells at day 60. Thereafter, a decreasing level of p38MAPK was seen along with the progression of bile duct cell transformation (Fig. 1a). Moreover, with a high CD44v8–10 expression of the bile duct cells there was a negative signal of p38MAPK activation; conversely, positive p38MAPK activation was seen in low CD44v8–10 expressed bile duct cells during cholangiocarcinogenesis (Fig. 1b). These results indicate that CD44s and CD44v8–10 are highly expressed during cholangiocarcinogenesis and are related to the increased regulation of redox status. This provides an advantage for cancer cells to survive in the high oxidative stress conditions that are associated with the CD44v8–10–xCT system. The resistant cells may increase and develop into tumor cells.
Figure 1

Upregulation of CD44 was negatively associated with downregulation of p38 during Opisthorchis viverrini (Ov)‐induced carcinogenesis in hamster. (a) Increased expression of standard CD44 (CD44s) and CD44 variant (CD44v) and decreased signal of phospho‐p38 during Ov‐induced cholangiocarcinoma genesis at 60, 90, 120, and 180 days post‐Ov infection were observed using immunohistochemical techniques. (b) Colocalization shows the converse correlation of CD44v8–10 and phospho‐p38. Magnification, ×40.

Upregulation of CD44 was negatively associated with downregulation of p38 during Opisthorchis viverrini (Ov)‐induced carcinogenesis in hamster. (a) Increased expression of standard CD44 (CD44s) and CD44 variant (CD44v) and decreased signal of phospho‐p38 during Ov‐induced cholangiocarcinoma genesis at 60, 90, 120, and 180 days post‐Ov infection were observed using immunohistochemical techniques. (b) Colocalization shows the converse correlation of CD44v8–10 and phospho‐p38. Magnification, ×40.

CD44 expression in CCA patients

Chronic inflammatory responses of cytokine signaling are the key molecular mechanisms underlying Ov‐associated CCA, whereas aberrant growth factor signaling plays a major role in non‐Ov associated CCA.35 We thus evaluated the different patterns of CD44v8–10 and p38MAPK expression in Ov‐ and non‐Ov‐related CCA liver tissues. Our results showed that there was a negative association between phospho‐p38MAPK and CD44v8–10 in Ov‐associated CCA patients (76%). This was higher than in non‐Ov‐associated CCA patients (52%), although CD44v8–10high expression was seen in non‐Ov‐related CCA patients (50%), which was as high as in Ov‐related CCA patients (43%; Fig. 2a). A negative correlation between CD44v8–10 and phospho‐p38MAPK expression in Ov‐associated CCA patients was observed (−0.098, P = 0.171), whereas a positive correlation of CD44v8–10 with phospho‐p38MAPK was seen in non‐Ov‐associated CCA patients (0.121, P = 0.137). This finding indicates that the expression of CD44v8–10 in CCA with Ov infection is related with ROS signaling (p38MAPK), but it is not seen in patients with non‐Ov‐associated CCA.
Figure 2

Combination of CD44 variants 8–10 (CD44v8–10) and phospho‐p38 expression predicts cholangiocarcinoma (CCA) survival. (a) Different expression patterns of CD44v8–10 and phospho‐p38 in cancer cells of patients with Opisthorchis viverrini (Ov)‐associated and non‐Ov‐associated CCA showed that 76% of Ov‐associated CCA patients have a negative association between CD44v8–10 and phospho‐p38 expression. (b) Immunohistochemistry analysis revealed that 43% of CCA patients had high expression of CD44v8–10 and 29% of CCA patients have positive phospho‐p38 in Ov‐associated CCA. (c) Colocalization of Ov‐associated CCA tissues indicates that CD44v8–10 expression is conversely related to the phospho‐p38 signal. (d) Kaplan–Meier method of survival analysis in Ov‐associated CCA patients in two groups show CD44v8–10high and negative to phospho‐p38 compared with CD44v8–10low and positive to phospho‐p38. *P < 0.05 was considered statistically significant.

Combination of CD44 variants 8–10 (CD44v8–10) and phospho‐p38 expression predicts cholangiocarcinoma (CCA) survival. (a) Different expression patterns of CD44v8–10 and phospho‐p38 in cancer cells of patients with Opisthorchis viverrini (Ov)‐associated and non‐Ov‐associated CCA showed that 76% of Ov‐associated CCA patients have a negative association between CD44v8–10 and phospho‐p38 expression. (b) Immunohistochemistry analysis revealed that 43% of CCA patients had high expression of CD44v8–10 and 29% of CCA patients have positive phospho‐p38 in Ov‐associated CCA. (c) Colocalization of Ov‐associated CCA tissues indicates that CD44v8–10 expression is conversely related to the phospho‐p38 signal. (d) Kaplan–Meier method of survival analysis in Ov‐associated CCA patients in two groups show CD44v8–10high and negative to phospho‐p38 compared with CD44v8–10low and positive to phospho‐p38. *P < 0.05 was considered statistically significant. Interestingly, a high membranous CD44v8–10 signal (CD44v8–10high) and positive phospho‐p38MAPK expression was cumulative in 43% (42/97) and 29% (22/97) of CCA cases, respectively (Fig. 2b; Table 1). In addition, the colocalization of CD44v8–10 and phospho‐p38MAPK showed a CD44v8–10‐positive signal that was inversely correlated with p38MAPK (Fig. 2c). The CD44v8–10high patients with a negative phospho‐p38MAPK had a significantly shorter survival than CD44v8–10low patients with a positive phospho‐p38MAPK (P = 0.030; Fig. 2d). Moreover, CD44shigh expression was significantly associated with a high level of metastasis (P = 0.043) (Table 1). Our observations suggest that CD44v8–10 plays a role in the regulation of the ROS defense system (high CD44v8–10, negative p38MAPK), which is linked to a poor prognosis in CCA patients.
Table 1

Correlation between the expression of standard CD44‐positive, CD44 variants 8–10‐positive, total p38MAPK‐positive, and phospho‐p38MAPK‐positive cholangiocarcinoma cells in patients with Opisthorchis viverrini‐associated cholangiocarcinoma

Clinicopathologic data n Expression of CD44Expression of p38MAPK
Standard P‐valueVariant P‐valueTotal form P‐valueActive form P‐value
LowHighLowHighNegativePositiveNegativePositive
Age, years
<584925240.41831180.22225240.68637120.809
≥58482028242422263810
Sex
Male6930390.38037320.37437320.12352170.596
Female28151318101018235
Histological types
Non‐papillary6828400.12636320.27333351.00054140.442
Papillary29171219101415218
Metastasis
No metastasis4526190.043a 27180.68124210.41935101.000
Metastasis521933282423294012

P ≤ 0.05 was considered statistically significant.

Correlation between the expression of standard CD44‐positive, CD44 variants 8–10‐positive, total p38MAPK‐positive, and phospho‐p38MAPK‐positive cholangiocarcinoma cells in patients with Opisthorchis viverrini‐associated cholangiocarcinoma P ≤ 0.05 was considered statistically significant.

CD44 variants 8–10 regulate cell surface expression of xCT to promote ROS defense in CD44v8–10‐positive CCA cell lines

Based on the expression profile of Ov‐induced hamster and human CCA tissues, we next explored the function of CD44v8–10 in relation to the ROS defense system through stabilizing xCT. The levels of CD44s, CD44v8–10, and xCT in three human CCA cell lines (KKU‐213, KKU‐214, and KKU‐100) were evaluated by using flow cytometry analysis. High CD44v8–10 and xCT expression on cell surfaces was found in KKU‐213 and KKU‐214. For KKU‐100, a low signal for both xCT and CD44v8–10 was observed (Fig. 3a). CD44v8–10high‐KKU‐213 and KKU‐214 cells were transiently transfected either with two siRNAs of specifically targeted CD44 mRNA (CD44 siRNA) or a control siRNA. The expression of CD44v8–10 was successfully decreased approximately 3‐fold compared to the KKU‐214 control, whereas a 1‐fold suppression was observed in KKU‐213. Furthermore, CD44 siRNA‐transfected cells had a lower xCT signal than control siRNA‐transfected cells (Fig. 3b). These results suggest that CD44v8–10 could stabilize xCT on membranes in CCA cell lines. Thus, we next examined the effects of CD44v8–10 suppression on the regulation of the ROS defense system by monitoring GSH and ROS levels either in normal or oxidative stress conditions. The GSH level was clearly decreased whereas the ROS was increased with CD44v8–10 reduction under oxidative stress (Fig. 3c,d). An activation of p38MAPK, which regulates several protein kinases involved in cellular function, was seen (Fig. 3e). These results revealed that suppression of the CD44v8–10–xCT system could contribute to the induction of an intracellular ROS level through decreasing GSH synthesis.
Figure 3

Knockdown of CD44 shows that CD44 variants 8–10 (CD44v8–10) and xCT expression on the surface of cholangiocarcinoma (CCA) cells is related to the regulation of redox status. (a) Basal levels of standard CD44 (CD44s), CD44v8–10 and xCT in CCA cell lines were determined using flow cytometry. (b) Flow cytometric analysis of CD44v8–10 and xCT expression on the cell surface showed that the xCT level was decreased in CCA cells transfected with CD44 siRNAs. Cells with control or CD44 siRNAs transfection were incubated in the presence or absence of 500 μM H2O2 for 20 min, and then stained with dichloro‐dihydro‐fluorescein diacetate (DCFH‐DA) for flow cytometry analysis (c) and glutathione assay (d). (e) Upregulation of phospho‐p38 was evaluated by Western blotting in knockdown of CD44. RFI, relative fluorescence intensity.

Knockdown of CD44 shows that CD44 variants 8–10 (CD44v8–10) and xCT expression on the surface of cholangiocarcinoma (CCA) cells is related to the regulation of redox status. (a) Basal levels of standard CD44 (CD44s), CD44v8–10 and xCT in CCA cell lines were determined using flow cytometry. (b) Flow cytometric analysis of CD44v8–10 and xCT expression on the cell surface showed that the xCT level was decreased in CCA cells transfected with CD44 siRNAs. Cells with control or CD44 siRNAs transfection were incubated in the presence or absence of 500 μM H2O2 for 20 min, and then stained with dichloro‐dihydro‐fluorescein diacetate (DCFH‐DA) for flow cytometry analysis (c) and glutathione assay (d). (e) Upregulation of phospho‐p38 was evaluated by Western blotting in knockdown of CD44. RFI, relative fluorescence intensity.

Sulfasalazine suppresses CCA cell proliferation and activation of p38MAPK , resulting in induction of autophagic cell death in CCA cell lines

We next confirmed whether the function of the CD44v8–10–xCT system was related to the regulation of ROS defense by using SSZ. Our observations showed that SSZ‐treated CD44v8–10high‐expressing CCA cells had higher ROS levels than SSZ‐treated CD44v8–10low‐expressing CCA cells. We used BSO, an inhibitor of GSH synthesis, as a positive control. Surprisingly, SSZ‐treated CCA cells have intracellular ROS levels as high as BSO‐treated cells in high expression xCT cells (KKU‐213 and KKU‐214), whereas low expression xCT cells (KKU‐100), which were treated with SSZ, had lower ROS levels than BSO‐treated cells (Fig. 4a). Similarly, a reduced intracellular GSH level was found after SSZ treatment in parallel with BSO treatment (Fig. 4b). These results suggest that a CD44v8–10–xCT‐dependent ROS defense system exists with high CD44v8–10 and xCT expression, whereas low expression cells were not affected. We further examined whether the CD44v8–10–xCT system can be a potential target for CCA treatment. The results clearly showed that KKU‐213 and KKU‐214 were more sensitive to SSZ treatment than KKU‐100 (Fig. 4c). Cell death induction was also inhibited by Trolox treatment, indicating the reverse effect of the oxidative stress phenotype by SSZ treatment (Fig. 4d). Our results show that SSZ‐treated cells proliferated significantly more slowly than control cells in all cell lines (Fig. 4e). We also showed that phospho‐p38MAPK, p21 (cell cycle inhibitor), and LC3B‐II (autophagic protein) expression was upregulated after SSZ treatment (Fig. 4f,g), hence an inhibition of cell proliferation was stimulated by p38MAPK, possibly through p21 signaling, and cell death processes were induced by the autophagic pathway. Our findings suggest that SSZ could suppress cell growth possibly through ROS–p38MAPK–p21 signaling and induce cell death through the activation of ROS–p38MAPK signaling‐dependent autophagic processes.
Figure 4

Sulfasalazine (SSZ), an xCT inhibitor, could inhibit cell growth and activate cell death possibly through the reactive oxygen species (ROS)–p38–p21‐dependent autophagy pathway. SSZ‐treated cholangiocarcinoma (CCA) cell lines showed that the ROS level was increased (a) and reduced glutathione (GSH) was decreased (b). (c) Percentage of CCA cell survival after treatment with various concentrations of SSZ for 48 h, together with the presence or absence of 6‐hydroxy‐2,5,7,8‐tetramethylchroman‐2‐carboxylic acid (Trolox; antioxidant) (d), showed that CCA cells sensitized to SSZ treatment could recover from antioxidants. (e) Cell proliferation inhibition effect of SSZ on CCA cell lines. *P < 0.05; **P < 0.01. (f) Overexpression of ROS–p38 signaling downstream proteins (p38), as well as autophagic‐activated proteins (LC3B), was observed. (g) Nuclear localization of p21 (cell cycle inhibitor) was revealed using immunofluorescence. BSO, buthionine sulphoximine.

Sulfasalazine (SSZ), an xCT inhibitor, could inhibit cell growth and activate cell death possibly through the reactive oxygen species (ROS)–p38p21‐dependent autophagy pathway. SSZ‐treated cholangiocarcinoma (CCA) cell lines showed that the ROS level was increased (a) and reduced glutathione (GSH) was decreased (b). (c) Percentage of CCA cell survival after treatment with various concentrations of SSZ for 48 h, together with the presence or absence of 6‐hydroxy‐2,5,7,8‐tetramethylchroman‐2‐carboxylic acid (Trolox; antioxidant) (d), showed that CCA cells sensitized to SSZ treatment could recover from antioxidants. (e) Cell proliferation inhibition effect of SSZ on CCA cell lines. *P < 0.05; **P < 0.01. (f) Overexpression of ROSp38 signaling downstream proteins (p38), as well as autophagic‐activated proteins (LC3B), was observed. (g) Nuclear localization of p21 (cell cycle inhibitor) was revealed using immunofluorescence. BSO, buthionine sulphoximine.

Discussion

In the present study, we found an increasing expression of both CD44s and CD44v8–10 starting at day 60 until day 180 after Ov infection along with the transformation of normal bile duct cells to cells with hyperplasia, and dysplasia to CCA, although cytoplasmic CD44 was seen in hamster CCA tissues rather than membrane‐positive staining. We hypothesized that CD44 could move from the membranes of the bile duct cells to localize in the cytoplasm when these cells became malignant.36 Our results indicate that an upregulation of CD44, including CD44s and CD44v8–10, was inversely correlated with downstream ROS signaling phospho‐p38MAPK expression in the hamster carcinogenesis group when compared to the untreated group. We assumed that an overproduction of oxidants occurs during Ov‐induced cholangiocarcinogenesis. This not only damages biomolecules, but also induces the expression of CD44 as well as CD44 variant forms. Even though oxidant‐damaged cells normally undergo programmed cell death, some of the damaged cells, which we believe are those that express CD44, can survive, proliferate, and subsequently transform into tumor cells that eventually develop into tumor mass. A previous study showed that CD44‐positive cells in normal mice are supposed to be candidates for the cell origin of gastric CSCs.37 In this study, we hypothesized that CD44‐positive cells are also potential candidates for the cell origin of CCA stem‐like cells. These cells could be able to adapt their redox status regulation to maintain redox homeostasis during CCA genesis, possibly through enhancing GSH production by way of the CD44v8–10–xCT system, resulting in evasion of cell death. This study provides the first evidence in CCA to explain the linkage between the mechanism of oxidative stress and cancer development through the expression of the CD44 CSC marker, which leads to the alteration of redox regulating status causing cells to resist apoptosis and finally develop into cancer. Standard CD44 has been reported to contribute to the epithelial–mesenchymal transition process that plays important roles in cancer metastasis through activation of transforming growth factor‐β and Akt.2 Previous evidence suggests that CCA patients with a high expression of CD44s have a poor prognosis,38 and an in vitro study of the reduction of CD44s showed that CD44s expression could facilitate cell invasion and cell migration in CCA.39 Similarly, the present work shows that CD44shigh expression in CCA patients had significantly higher metastasis potential than CD44slow expression. Furthermore, CD44v8–10 enhances mechanisms of the ROS defense system.22 The IHC staining of human CCA tissues indicated the expression of phospho‐p38MAPK downstream of ROS signaling, which was negatively associated with upregulation of CD44v8–10. We thereby hypothesized that CD44v8–10 might regulate the ROS defense system (high CD44v8–10, negative p38MAPK), linking to the poor prognosis for CCA patients. A relationship between CD44v8–10 and redox status regulation in human CCA tissues was confirmed using an siRNA assay. Our findings revealed that CD44v8–10 regulates redox status by stabilizing xCT, resulting in a reduced GSH level and decrease in the ROS level. This, in turn, led to suppression of p38MAPK activation. Furthermore, the cells treated with SSZ also showed the ability to modify their intracellular redox status and suppress the ROS defense system by blocking GSH synthesis. The alteration of redox status can activate ROS–p38MAPK signaling, resulting in inhibition of cell growth through the accumulation of p21. Additionally, ROS–p38MAPK signaling8 may affect the induction of autophagy through increasing the level of Atg proteins, such as beclin 1 and Atg5.12, 40, 41, 42 Many studies have shown that tumor progression, relapse, and metastasis are driven by CSCs, which are identified by cell surface markers including CD44. Recently, it was shown that CD44v8–10, but not CD44s, play roles in the regulation of redox status through specifically interacting with xCT in CSCs. An xCT–plasma membrane amino acid transporter controls the exchange of extracellular cystine and intracellular glutamate (xc− system), which contributes to GSH synthesis. This covalently interacts with CD98hc.43 Moreover, several studies have shown that high xCT expression is associated with cell proliferation and anticancer drug‐resistant properties.44 Additionally, treatment of the xCT inhibitor selectively induced apoptosis in CD44v8–10‐expressing cells without affecting CD44v8–10‐negative cells in head and neck squamous cell carcinoma.27 Imbalance of oxidants/antioxidants leads to the alteration of cell signaling, especially the ROS–p38MAPK signal. p38MAPK is a class of MAPK that negatively controls carcinogenesis. p38MAPK responds to stress stimuli, and is involved in cell differentiation, apoptosis, and autophagy. Moreover, p38MAPK has been reported to contribute to suppression of carcinoma development by inhibiting cell growth and the induction of cell death. It can directly activate p21, which is an important cell cycle inhibitor,8 resulting in G1 cell cycle arrest9 and senescence.10 Furthermore, it has also been reported that p38MAPK signaling could trigger autophagy to conversion of LC3B‐I to LC3B‐II through increasing the level of Atg proteins.12 Therefore, the inhibition of the CD44v8–10–xCT system contributes an oxidative stress to cancer cells, which enhances intracellular ROS levels, resulting in suppression of p38MAPK‐ and p21‐mediated proliferation inhibition as well as stimulation of p38MAPK‐mediated autophagic pathway in CCA. Although Ov infection is defined as a major risk factor of CCA in Thailand, there are also several other causes of CCA development. This study shows a distinct pattern of regulating redox status protein in Ov‐associated and non‐Ov‐associated CCA. We observed that the negative association of CD44v8–10 and p38MAPK expression in Ov‐associated CCA patients correlated with clinicopathological data, whereas this was not seen in non‐Ov‐associated CCA patients. We previously reported that Ov‐induced CCA can cause DNA damage through oxidant production.30, 45, 46 Therefore, Ov infection may lead to increased expression of CD44, which might, in turn, interact with xCT and enhance antioxidants to maintain the intracellular redox status by taking up cystine, the key factor in GSH synthesis. Our previous study also showed differences in the frequency of gene mutation between Ov and non‐Ov associated CCA: p53 mutation was frequently found in Ov‐associated CCA, whereas KRAS mutation was frequently observed in non‐Ov CCA.47 Activity of p53 was related to the suppression of CD44 expression, thus p53 mutation could contribute to enhancing the expression of CD44 in Ov‐associated CCA.48 Taken together, our present results lead to the conclusion that an accumulation of CD44v8–10 causes suppression of p38MAPK expression in transforming bile duct cells and links to a poor prognosis in CCA patients. Depletion of CD44v8–10 induced the loss of xCT from the cell surface and increased the ROS level in an in vitro model. Sulfasalazine could suppress cell growth and trigger autophagic cell death. Therefore, an xCT‐targeting drug may improve CCA treatment by sensitizing CCA cells to the available chemotherapeutic drugs (e.g., gemcitabine) by blocking the mechanism of the cell's ROS defensive system.

Disclosure Statement

The authors have no conflict of interest. autophagy‐related buthionine sulphoximine cholangiocarcinoma standard CD44 CD44 variant cancer stem cell dichlorofluorescein dichloro‐dihydro‐fluorescein diacetate reduced glutathione immunohistochemical microtubule‐associated protein 1A/1B‐light chain 3 Opisthorchis viverrini reactive oxygen species sulfasalazine 6‐hydroxy‐2,5,7,8‐tetramethylchroman‐2‐carboxylic acid
  49 in total

1.  Prospective identification of tumorigenic prostate cancer stem cells.

Authors:  Anne T Collins; Paul A Berry; Catherine Hyde; Michael J Stower; Norman J Maitland
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

2.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Authors:  Supak Yothaisong; Hasaya Dokduang; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Gregory J Riggins; Watcharin Loilome
Journal:  Tumour Biol       Date:  2013-07-06

3.  Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis.

Authors:  Malinee Thanee; Watcharin Loilome; Anchalee Techasen; Nisana Namwat; Thidarut Boonmars; Chawalit Pairojkul; Puangrat Yongvanit
Journal:  Asian Pac J Cancer Prev       Date:  2015

4.  Protein A, avidin, and biotin in immunohistochemistry.

Authors:  S M Hsu; L Raine
Journal:  J Histochem Cytochem       Date:  1981-11       Impact factor: 2.479

5.  CD44+ slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E2 in gastric tumorigenesis.

Authors:  Takatsugu Ishimoto; Hiroko Oshima; Masanobu Oshima; Kazuharu Kai; Ryota Torii; Takashi Masuko; Hideo Baba; Hideyuki Saya; Osamu Nagano
Journal:  Cancer Sci       Date:  2009-12-18       Impact factor: 6.716

6.  Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug.

Authors:  P W Gout; A R Buckley; C R Simms; N Bruchovsky
Journal:  Leukemia       Date:  2001-10       Impact factor: 11.528

Review 7.  Redox regulation in stem-like cancer cells by CD44 variant isoforms.

Authors:  O Nagano; S Okazaki; H Saya
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

8.  The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation.

Authors:  Geum-Yi Kim; Stephen E Mercer; Daina Z Ewton; Zhongfa Yan; Kideok Jin; Eileen Friedman
Journal:  J Biol Chem       Date:  2002-06-10       Impact factor: 5.157

9.  Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway.

Authors:  R-S Chen; Y-M Song; Z-Y Zhou; T Tong; Y Li; M Fu; X-L Guo; L-J Dong; X He; H-X Qiao; Q-M Zhan; W Li
Journal:  Oncogene       Date:  2008-11-17       Impact factor: 9.867

Review 10.  Liver fluke induces cholangiocarcinoma.

Authors:  Banchob Sripa; Sasithorn Kaewkes; Paiboon Sithithaworn; Eimorn Mairiang; Thewarach Laha; Michael Smout; Chawalit Pairojkul; Vajaraphongsa Bhudhisawasdi; Smarn Tesana; Bandit Thinkamrop; Jeffrey M Bethony; Alex Loukas; Paul J Brindley
Journal:  PLoS Med       Date:  2007-07       Impact factor: 11.069

View more
  23 in total

Review 1.  Roles of mitochondria in liver cancer stem cells.

Authors:  Ching-Wen Chang; Jeng-Fan Lo; Xin Wei Wang
Journal:  Differentiation       Date:  2019-05-30       Impact factor: 3.880

2.  miR-28-5p inhibits cholangiocarcinoma progression and predicts good prognosis of patients.

Authors:  Tingsong Chen; Hao Wang; Hongzhu Yan
Journal:  Cell Cycle       Date:  2022-06-07       Impact factor: 5.173

3.  High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection.

Authors:  Attapol Titapun; Vor Luvira; Tharatip Srisuk; Apiwat Jareanrat; Vasin Thanasukarn; Malinee Thanee; Prakasit Sa-Ngiamwibool; Sureerat Padthaisong; Kassaporn Duangkumpha; Manida Suksawat; Watcharin Loilome; Paiboon Sithithaworn; Anchalee Techasen; Bandit Thinkhamrop; Alexa Dzienny; Ayse Caglayan; David Park; Simran Mahmud; Narong Khuntikeo
Journal:  Int J Gen Med       Date:  2021-06-01

4.  Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models.

Authors:  Malinee Thanee; Sureerat Padthaisong; Manida Suksawat; Hasaya Dokduang; Jutarop Phetcharaburanin; Poramate Klanrit; Attapol Titapun; Nisana Namwat; Arporn Wangwiwatsin; Prakasit Sa-Ngiamwibool; Narong Khuntikeo; Hideyuki Saya; Watcharin Loilome
Journal:  Cancer Metab       Date:  2021-03-16

5.  CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.

Authors:  Malinee Thanee; Watcharin Loilome; Anchalee Techasen; Eiji Sugihara; Shogo Okazaki; Shinya Abe; Shiho Ueda; Takashi Masuko; Nisana Namwat; Narong Khuntikeo; Attapol Titapun; Chawalit Pairojkul; Hideyuki Saya; Puangrat Yongvanit
Journal:  Cancer Sci       Date:  2016-06-20       Impact factor: 6.716

6.  Cancer cell lines involving cancer stem cell populations respond to oxidative stress.

Authors:  Açelya Yilmazer
Journal:  Biotechnol Rep (Amst)       Date:  2017-11-23

Review 7.  Biliary tract cancer stem cells - translational options and challenges.

Authors:  Christian Mayr; Matthias Ocker; Markus Ritter; Martin Pichler; Daniel Neureiter; Tobias Kiesslich
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

8.  Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma.

Authors:  Zijing Lin; Jianping Gong; Guochao Zhong; Jiejun Hu; Dong Cai; Lei Zhao; Zhibo Zhao
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

9.  Antifibrotic effect of xanthohumol in combination with praziquantel is associated with altered redox status and reduced iron accumulation during liver fluke-associated cholangiocarcinogenesis.

Authors:  Wassana Jamnongkan; Malinee Thanee; Puangrat Yongvanit; Watcharin Loilome; Raynoo Thanan; Phongsaran Kimawaha; Tidarat Boonmars; Runglawan Silakit; Nisana Namwat; Anchalee Techasen
Journal:  PeerJ       Date:  2018-01-22       Impact factor: 2.984

Review 10.  Redox regulation in tumor cell epithelial-mesenchymal transition: molecular basis and therapeutic strategy.

Authors:  Jingwen Jiang; Kui Wang; Yan Chen; Haining Chen; Edouard C Nice; Canhua Huang
Journal:  Signal Transduct Target Ther       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.